Abstract The cAMP response element-binding protein (CREB) is a transcription factor that mediates the cellular response to metabolic and mitogenic signals. Whether CREB contributes to vascular function has received little attention, especially in relation to the processes associated with atherosclerotic disease progression and restenosis. This study examined the involvement of CREB in the mitogenic actions of angiotensin II (AngII), a growth factor that promotes neointimal hyperplasia in response to vascular injury. Treatments were performed on quiescent vascular smooth muscle cells (VSMCs) obtained from a porcine explant model. Organ culture was performed on porcine hearts subjected to angioplasty ex vivo. Stimulation of VSMCs with AngII resulted in transient CREB phosphorylation. Proliferation of smooth muscle cells in response to AngII was reduced by 90 % after infection with adenovirus expressing dominantnegative killer CREB (kCREB) mutant. Likewise, expression of kCREB prevented angioplasty-induced neointimal hyperplasia. AngII-induced CREB phosphorylation was independent of cAMP activation. Examination of putative CREB kinases revealed that MSK was responsible for phosphorylating CREB. In addition, inhibition of PKC revealed that this kinase operates upstream and activates MSK. These results indicate that activation of CREB via PKC and MSK is essential for SMC proliferation in response to AngII.
Introduction
Humoral factors secreted in response to vascular injury are responsible for mediating the various processes that enable repair of the damaged tissue. However, production of these agents either in above normal amounts or for an increased length of time can trigger the onset of various pathophysiological conditions, including both atherosclerosis and restenosis. Among the factors commonly released following injury to vascular tissue is AngII (Newby and Zaltsman 2000) . This peptide hormone operates by binding to the AT 1 receptor (AT 1 R), which in turn activates specific intracellular signal transducers such as MAP kinase, phosphatidylinositol-3-kinase (PI3-kinase) and Rho that influence smooth muscle cell (SMC) function (Touyz and Schiffrin 2000) . A consequence of these actions is the conversion of SMCs from their normal contractile state to the synthetic phenotype, thereby enabling these cells to proliferate and migrate, both essential processes for tissue repair but also key elements in vascular pathologies (reviewed in Owens et al. 2004) .
Control of SMC phenotype is presumed to be mediated by transcription factors that are activated in response to various extracellular signals (Owens 2007) . The cAMP response element-binding protein (CREB) is one of these transcription factors, and is an important nuclear target of cyclic nucleotide signaling. Klemm et al. (2001) were the first to report that CREB was a molecular "off-switch", and that increased cellular content of CREB, along with its activation via phosphorylation, maintains SMCs in a differentiated state. Thus, deactivation of CREB would be required for the phenotypic switch that enables SMC proliferation and migration. In contrast, Funakoshi et al. (2002) subsequently reported that CREB phosphorylation occurred in response to AngII, and that there was an association between CREB modification and SMC hypertrophy. One of the conclusions reached in this study was that CREB phosphorylation was mediated by PKA. However, this contrasts with other reports showing that cAMP-induced stimulation of PKA results in suppression of SMC growth, rather than its promotion . As the AT 1 R, the receptor primarily responsible for AngII effects on SMCs (Mehta and Griendling 2007) , is a G αi -coupled receptor that blocks cAMP production, it would be reasonable to expect that AngII activation would result in inhibition of cAMP-mediated activities, thereby leading to SMC growth. As the data implicating PKA were based on the actions of the pharmacological inhibitor H89, which is a compound also capable of blocking the actions of numerous other kinases (Lochner and Moolman 2006; Murray 2008) , we sought to investigate whether the PKA-independent effects of H89 could be used to rationalize the contradicting results. Thus, the purpose of this study was to describe in greater detail the relationship between CREB, AngII and PKA in SMCs, specifically focusing on its role in SMC proliferation in relation to vascular injury, as well as to characterize the CREB kinase and other potential upstream regulators that mediate this event.
Materials and methods
Cell culture Primary cultures of porcine coronary artery SMCs were generated from the left anterior descending (LAD) coronary artery of whole swine hearts obtained from a local abattoir, as previously described (Saward and Zahradka 1997b) . Briefly, LAD arteries were flushed with PBS (consisting of 0.1 M Na 3 PO 4 and 0.9 % NaCl) + 10× antibiotic-antimycotic, then dissected out and cleaned of adhering fat or cardiac tissue. Cells were obtained from migration of cells from cut segments onto culture plates and maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 20 % FBS+1× antibiotic-antimycotic. Only passages 3 to 5 were used to maintain consistency between cultures. Quiescence was induced by transferring cells at 80 % confluency into serum-free media consisting of DMEM supplemented with 0.1 mM pyruvate, 5 μg/mL transferrin, 1 nM selenium and 200 μM ascorbate (PTSA).
Western blotting Extracts prepared by direct addition of 250μl 2× SDS/gel loading buffer to cells in 6-well culture dishes were loaded onto either 10 % or 7.5 % polyacrylamide gel. Following electrophoresis, the proteins were transferred to PVDF membrane and stained with antibodies to CREB (Upstate & Cell Signaling), Ser-133 phospho-CREB (Upstate & Cell Signaling), phospho-PKD, phospho-MSK, MSK, phospho-p90RSK or β-tubulin (all from Cell Signaling). Band intensities were quantified as previously described .
Immunofluorescence Epifluorescence microscopy of SMCs was conducted as previously described (Saward and Zahradka 1997a) .
Adenovirus construction and infection Dominant-negative (DN) killer CREB (kCREB) cDNA (RSVKCREB), generously provided by Richard H. Goodman (Oregon Health and Sciences University, Portland), was subcloned directly into the pSHUTTLE-CMV vector supplied in the AdEasy Vector System (Quantum Biotechnologies). The resulting adenoviral particles, designated as Ad-kC, were quantified by cytopathic titration as directed in the AdEasy Vector System manual. The Ad5.CMV-LacZΔE1/ΔE3 construct expressing β-galactosidase (β-gal) provided in the AdEasy kit, designated Ad-N, and an empty adenoviral vector, designated Ad-mt, were used as controls.
DNA synthesis assay Cultures of quiescent SMCs were exposed to adenoviral particles 24 h prior to treatment with AngII. DNA synthesis was measured by incubating the cells with 1μCi [
3 H]-thymidine, added 24h after mitogen stimulation, for 48h as previously described (Saward and Zahradka 1997a) .
Coronary artery organ culture Porcine hearts were subjected to angioplasty ex vivo as previously described (Wilson et al. 1999) . A standard angioplasty catheter (20×3.5 mm) was inserted into the LAD coronary artery and passed along, distal to the first major bifurcation. The catheter was inflated to five atmospheres for 1 min. Coronary artery segments were extracted and maintained in culture for 14 days. Appropriate treatments (losartan or adenoviral particles) were added to the culture medium following each media change (every second day) over the 14-day incubation period. Vessel segments stained with Lee's methylene blue were analyzed with StainPoint software (Lynx Graphics Ltd., www.lynxgl.com) to quantify the neointimal index as intimal area/medial area (Wilson et al. 1999) .
cAMP assay The cAMP levels of SMCs were measured with a cAMP EIA kit (Cayman Chemical) according to the manufacturer's instructions.
Statistical analysis Data are graphically represented as means ± SEM. All experiments were replicated at least 3 times, with each replicate employing independent cell or vessel isolations. Treatment means were compared using one-way ANOVA. Significance was set at the 5 % level (p <0.05).
Results
AngII stimulates CREB phosphorylation via the AT 1 R Western blot analysis with an antibody that recognizes CREB phosphorylation at Ser-133 was used to monitor the effects of AngII stimulation of SMCs. CREB phosphorylation was detectable within 2 min after treatment of quiescent coronary artery SMCs with 1 μM AngII, and returned to basal levels after 30 min (Fig. 1a) . Immunofluorescence staining of SMCs with the same antibody revealed phosphorylated CREB was present in the nuclei of all AngII-treated cells (Fig. 1b) . In order to determine which receptor mediated CREB activation in response to AngII, CREB phosphorylation was measured in the presence of either an AT 1 R (Losartan) or an AT 2 R (PD123319) blocker. This experiment (Fig. 1c) established that CREB activation by AngII is mediated exclusively by the AT 1 R.
Expression of dominant-negative CREB prevents SMC proliferation and neointimal hyperplasia AngII is an SMC mitogen (Louis et al. 2011) , which suggests CREB activation may be involved in the proliferation of these cells. To test this possibility, adenoviral particles capable of expressing DN-kCREB (Walton et al. 1992) were prepared and shown to increase the cellular content of CREB (Fig. 2a) . Although kCREB expression could not be tracked directly in individual cells due to the presence of endogenous CREB, analogous experiments with a GFP reporter established that the typical adenovirus infection efficiency in our SMCs is ≥75 %. Cultures of quiescent SMCs were then exposed to adenoviral particles 24 h prior to treatment with AngII. Monitoring thymidine incorporation established that neither the empty adenoviral vector (Ad-mt), nor the vector expressing β-gal (Ad-φ), blocked the stimulation of SMC proliferation by AngII (Fig. 2b) . In contrast, infection with Ad-kCREB prevented the increase in thymidine incorporation obtained with AngII ( Fig. 2c) , thus indicating that CREB activation is an essential event in SMC proliferation. Neointimal (NI) hyperplasia represents the proliferative response to vascular injury, and there is strong evidence supporting a role for AngII in this process (Moon et al. 2004; Wilson et al. 1999) . To investigate the possibility that CREB is also required for neointimal formation, an organ culture model of balloon angioplasty-induced damage was employed. In this model, coronary vessels of isolated pig hearts are subjected to angioplasty and segments placed into culture for up to 14 days. Neointimal formation is then monitored by morphometric analysis of the intimal area in relation to the media (Wilson et al. 1999 ). This model system was shown to be appropriate by the fact that CREB phosphorylation was increased in vessels 2 days after undergoing angioplasty and that blockade of the AT 1 receptor with losartan decreased the level of CREB phosphorylation (Fig. 3a) . Morphometric examination of the stained vessel sections showed that the neointimal area obtained in vessels incubated with Ad-kC was significantly reduced in comparison with injured vessels that were either untreated or exposed to Ad-φ (Fig. 3b) . Quantitative analysis of the data from all vessels indicated Ad-kC reduced the neointimal index, defined as the ratio between the intimal area and the medial area, by 53 % (Fig. 3b) . These results establish that CREB activation is an important component of the vascular response to injury.
PKA does not phosphorylate CREB in response to AngII The inhibitor H89, previously used to report a connection between AngII and PKA-stimulated cAMP mediation of CREB (Funakoshi et al. 2002) , is also a potent inhibitor of several other kinases known to affect cell proliferation (Lochner and Moolman 2006; Murray 2008) . We therefore reexamined this issue with other inhibitors of PKA, namely KT5720 (Kase et al. 1987) and PKI (Cheng et al. 1986) . When added to the cell culture medium, these compounds had no effect on the increase in CREB phosphorylation due to AngII treatment (Fig. 4a) , whereas H89 was effective in blocking CREB phosphorylation (Fig. 4b) . KT5720, like H89, has also been found to inhibit other kinases (Murray 2008 ) and thus cannot be used exclusively to distinguish the cellular actions of PKA. In contrast, the pseudosubstrate inhibitor PKI has been found to be highly selective. In support of these findings, it was shown that AngII treatment causes a decrease in cellular cAMP levels, thereby indicating that the AngII receptor is functional (Fig. 4c) . These data establish that PKA is likely between the intimal area to the medial area, was derived from morphological analysis of the vessel segments and is plotted as means ± SEM (n =8). The experiment was replicated three times. Significant differences (p <0.05) were identified with one-way ANOVA; *, significant increases relative to non-injured (NI); and #, reduction relative to balloon-injured (BI) vessels not involved in AngII-mediated CREB activation in SMCs, as previously proposed (Funakoshi et al. 2002) .
MSK meets the requirements of the CREB kinase and is likely downstream of PKC To identify the CREB kinase activated by AngII, phosphorylation of likely CREB kinase candidates was monitored by Western blotting after stimulation of quiescent SMCs with 1 μM AngII. We found that PKD, p90 RSK and MSK were all activated by AngII stimulation (Fig. 5a) ; however, only the MSK inhibitor SB747651 was able to prevent CREB phosphorylation (Fig. 5b) . These results show that multiple pathways are activated by AngII, but that the CREB kinase that is responsive to AngII in SMCs is MSK.
To further characterize the pathway by which AngII signals to CREB, we inhibited SMCs with the PKC inhibitor Bisindolylmaleimide (BIM) prior to stimulation with AngII. Results show that both CREB and MSK activation were blocked by PKC inhibition, indicating that PKC is likely upstream of these kinases (Fig. 5c) . However, since BIM inhibits several PKC isoforms and other isoform-specific inhibitors are lacking, we are currently unable to distinguish which isoform of PKC mediates activation of MSK.
Discussion
Activation of CREB in SMCs by AngII was previously reported by Funakoshi et al. (Funakoshi et al. 2002) . In this study, we have demonstrated that CREB activation in response to AngII stimulation promotes SMC proliferation and neointimal hyperplasia. Furthermore, we show that the kinase responsible for activating CREB in this instance is MSK, working downstream of PKC and independently of PKA or other cAMP-related signaling.
The cAMP-dependent kinase PKA stimulates Ser-133 phosphorylation of CREB in response to elevated intracellular levels of cAMP (Shaywitz and Greenberg 1999) . The AngII receptor operates through both G αq and G αi (Higuchi et al. 2007) ; the latter G protein mediates a decrease in the levels of cAMP (Fig. 4c) . Thus, under AngII-stimulated conditions, PKA activation should not occur, which contradicts the study by Funakoshi et al. (2002) who reported that PKA was activated in response to AngII stimulation. However, since the non-selective inhibitor H89 was used in their study, we sought to clarify this issue by comparing multiple inhibitors of PKA, including KT5720, PKI (Fig. 4a) and R p -cAMPS (data not shown). The inhibition constant (K i ) of H89 for PKA is in the micromolar range (Chijiwa et al. 1990 ) and, although it does effectively inhibit PKA, it has also been shown to inhibit other kinases and to exhibit non-PKA-based activities (Murray 2008) . Thus, alone, it is not the most suitable reagent for elucidating PKA function, despite its common use as such.
The same may be said of KT5720, while PKI and Rp-cAMPS exhibit greater selectivity. Nevertheless, a comparative analysis of all of these compounds has confirmed that PKA is likely not involved in the pathways leading to AngII-induced CREB phosphorylation in SMCs (Fig. 4a) . Consequently, inhibition of CREB activation by H89 is most likely explained by its non-PKA-selective effects. Interestingly, this includes the possibility of inhibition of the AT 1 R itself, since H89 has been shown to interfere with G protein receptor activation (Penn et al. 1999) . It should be noted that our identification of mitogen-and stress-activated kinase (MSK) as the CREB kinase activated by AngII is also supported by the findings of Funakoshi et al. (2002) , since H89 has been employed as an inhibitor of MSK as well as PKA (Khan et al. 2013) .
A few studies have started to delineate the sequence of events leading from AngII to CREB. Previous studies have linked growth factor activation to MSK and CREB via ERK or p38MAPK (Arthur and Cohen 2000; Deak et al. 1998 ). However, these groups used tyrosine kinases and cellular stresses to stimulate CREB phosphorylation. With respect to AngII, much evidence suggests involvement of the epidermal growth factor receptor (EGFR) (Eguchi et al. 2001; Funakoshi et al. 2002; Mifune et al. 2005) , and a review by Ichiki (2006) presented a model of transactivation of the EGFR by AT1R, eventually leading to MSK and CREB activation. Our study has confirmed using a highly selective inhibitor (Naqvi et al. 2012 ) that MSK is required for signal transduction from the AT1R to CREB and excludes PKA from this process. Likewise, the EGFR transactivation model of Ichiki (2006) also does not include PKA. However, in studies we have conducted, activation of CREB and MSK are not blocked by an EGFR inhibitor (data not shown), but by a selective G αq inhibitor. This suggests that an entirely novel pathway is activated in this case (Fig. 6) .
The proposed pathway in the review of Ichiki (2006) does not include a role for PKC, which we have shown here. Rather, MSK activation was linked to ERK1/2 and p38 MAPK (Pearce et al. 2010 ). However, a role for PKCdependent activation of MSK has been reported in the context of histone phosphorylation (Sutcliffe et al. 2011 ) and subsequent chromatin relaxation (Vermeulen et al. 2009 ). The group of Sutcliffe et al. (Sutcliffe et al. 2011 ) also found that PKC was associated with RNA polymerase II. Thus, PKC may directly associate with a chromatin-associated transcription complex that includes MSK and CREB for regulation of gene transcription.
The cellular and physiological consequences of CREB activation in SMCs remain highly contested. There are some convincing reports showing that CREB is down-regulated in response to signals of proliferation and migration, and in models of established vascular or metabolic disease (Herzig et al. 2001; Schauer et al. 2010; Watson et al. 2001) , implying that CREB activity is important for normal vascular physiology. In contrast, there is much evidence that CREB is activated in vascular cells by agents associated with the development of vascular disease (Funakoshi et al. 2002; Norata et al. 2003; Ono et al. 2006; Schauer et al. 2010) , especially in acute treatment settings where exposure to the agents ranged up to 60 min. While activation in these cases is temporary, there are also reports of elevated CREB after vascular injury, demonstrating an exacerbating effect of long-term, enhanced CREB activity (Tokunou et al. 2003) . These authors observed that inhibiting CREB with a dominant-negative adenovirus decreased SMC proliferation, which agrees with the findings of the current study (Fig. 2c) , although we obtained a 90 % inhibition of proliferation, as compared to the previously reported 40 % inhibition.
Our observations indicate that AngII is responsible for both short-and long-term CREB phosphorylation (Figs. 1 and 3 , respectively), supporting the hypothesis that chronic CREB activation likely exacerbates vascular disease by promoting neointimal formation (Tokunou et al. 2003) . Acute, transient activation (phosphorylation from 0 to 60 min) could be a factor relating to disease progression, where transient activation may modulate SMC phenotype, predisposing the cells to a different response in the case of subsequent chronic stimulation. Indeed, such a precedent has been set in a hypertensive cardiac model where the cellular responses to a combination of AngII and cAMP-elevating agent differed according to the activation state of cells (Sunga and Rabkin 1991) .
While controversy remains as to the exact role of CREB, it has emerged as an important player in vascular disease, and its inhibition interferes with critical processes involved in vascular disease development, including inflammation and SMC luminal accumulation (Ono et al. 2006; Tokunou et al. 2003) . The relevance of targeting CREB signaling for control of neointimal formation is further outlined in a study by Yang et al. (2010) , who used lentiviral delivery of RNA interference against CREB binding protein (CBP) and showed inhibition of both neointimal hyperplasia and re-endothelialization in vivo. Thus, CREB signaling has the potential to be a legitimate pharmacological target, keeping in mind that short-term, localized inhibition may be the most appropriate strategy.
Smooth muscle proliferation is an essential element of the repair processes activated by mechanical injury of vascular tissue through an alteration in the SMC phenotype, and an aggressive hyperplastic response from a vessel can trigger the formation of a neointimal lesion. Whether the damage results from an intrinsic (eg. hypertension) or an extrinsic (eg. revascularization) insult, the factors that mediate this proliferative response are likely identical. We have shown here that one of the key agents responsible for neointimal hyperplasia is AngII (Moon et al. 2004) , which initiates the vascular response to injury via activation of PKC, MSK and CREB.
